AbbVie Inc.
$514.13B- Market cap
- $454.36B
- Debt
- +$65.00B
- Cash
- −$5.23B
Capital structure 87% equity / 13% debt · EV / Revenue 8.41x · EV proxy / EBITDA proxy 22.15x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $454.36B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
FY 2026 ·
Decision snapshot: ABBV stock price at premium vs AAP $257.12 current versus $144.44 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AAP's multiple
Implied fair value · at ABBV's multiple
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 87% equity / 13% debt · EV / Revenue 8.41x · EV proxy / EBITDA proxy 22.15x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$87.89
Base
$110.94
Bull
$142.98
ADVANCE AUTO PARTS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
AUTOZONE INC
ABBV vs AZO
GENUINE PARTS CO
ABBV vs GPC
MONRO, INC.
ABBV vs MNRO
NORDSTROM INC
ABBV vs JWN
ROSS STORES, INC.
ABBV vs ROST
TARGET CORP
ABBV vs TGT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV’s superior growth, margins, and ROIC will continue and justify a premium multiple, then hold or buy selectively despite the model’s downside because the operating fundamentals are far stronger than AAP’s and ABBV remains inside its historical trading band.
On a relative basis, ABBV trades at a much richer multiple set than AAP, but ABBV also has materially stronger profitability and growth. The model’s implied price of $186.86 versus ABBV’s current $246.04 suggests a 24.1% downside under the P/E framework, yet ABBV is still within its historical band and far above AAP-implied low end.
Supporting Metrics